

# Maria do Sameiro Faria

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6253373/publications.pdf>

Version: 2024-02-01

74  
papers

952  
citations

516710

16  
h-index

501196

28  
g-index

75  
all docs

75  
docs citations

75  
times ranked

1275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2â€“5 and on dialysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1098-1113.	0.7	84
2	Inflammation, T-Cell Phenotype, and Inflammatory Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy. <i>Journal of Clinical Immunology</i> , 2008, 28, 268-275.	3.8	77
3	Nephropathy associated with heroin abuse in Caucasian patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2308-2313.	0.7	54
4	Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2â€“5 and on dialysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1114-1127.	0.7	51
5	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. <i>Disease Markers</i> , 2013, 35, 791-798.	1.3	45
6	Neutrophil Activation and Resistance to Recombinant Human Erythropoietin Therapy in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2008, 28, 935-940.	3.1	42
7	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. <i>Acta Haematologica</i> , 2009, 122, 226-229.	1.4	41
8	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2008, 28, 677-683.	3.1	36
9	Management of children with congenital nephrotic syndrome: challenging treatment paradigms. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1369-1377.	0.7	32
10	Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. <i>Hemodialysis International</i> , 2010, 14, 295-301.	0.9	26
11	Apoptosis of Peripheral CD4<sup>+</sup>T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. <i>Renal Failure</i> , 2011, 33, 138-143.	2.1	25
12	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. <i>Quality of Life Research</i> , 2015, 24, 1327-1335.	3.1	25
13	Impact of Pediatric Kidney Transplantation on Long-Term Professional and Social Outcomes. <i>Transplantation Proceedings</i> , 2011, 43, 120-124.	0.6	22
14	Oxidized lowâ€“density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. <i>Hemodialysis International</i> , 2012, 16, 481-490.	0.9	21
15	Type of Vascular access and Location in Online Hemodiafiltration and its Association with Patient's Perception of Health-Related Quality of Life. <i>Journal of Vascular Access</i> , 2014, 15, 175-182.	0.9	21
16	Altered Erythrocyte Membrane Protein Composition in Chronic Kidney Disease Stage 5 Patients under Haemodialysis and Recombinant Human Erythropoietin Therapy. <i>Blood Purification</i> , 2008, 26, 267-273.	1.8	18
17	Changes in Red Blood Cells Membrane Protein Composition during Hemodialysis Procedure. <i>Renal Failure</i> , 2008, 30, 971-975.	2.1	16
18	Main Determinants of PON1 Activity in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2012, 36, 317-323.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases. <i>Pediatric Nephrology</i> , 2019, 34, 649-655.	1.7	16
20	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	3.0	15
21	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-11.	4.0	15
22	Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient. <i>Pediatric Nephrology</i> , 2012, 27, 1583-1588.	1.7	13
23	Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis. <i>Scientific Reports</i> , 2021, 11, 14768.	3.3	13
24	Assessment of renal dopaminergic system activity during the recovery of renal function in human kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2667-2672.	0.7	12
25	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	12
26	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. <i>Hemodialysis International</i> , 2013, 17, n/a-n/a.	0.9	11
27	The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 709-716.	0.5	11
28	Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1371-1378.	2.9	11
29	Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. <i>The Open Clinical Chemistry Journal</i> , 2008, 1, 57-63.	0.7	11
30	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. <i>Renal Failure</i> , 2013, 35, 1392-1398.	2.1	10
31	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. <i>Renal Failure</i> , 2019, 41, 662-672.	2.1	10
32	HAEMODIALYSIS FOR CHILDREN UNDER THE AGE OF TWO YEARS. <i>Journal of Renal Care</i> , 2008, 34, 9-13.	1.2	9
33	Correlation between plasma calcium and coronary artery disease burden in patients with preserved renal function. <i>International Journal of Cardiology</i> , 2005, 98, 363-366.	1.7	8
34	Glomerular Filtration Rate and Coronary Artery Disease Burden in Patients with Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2007, 30, 464-468.	1.8	8
35	Partially Reversible Cardiomyopathy after Renal Transplant Associated with Anti-Troponin I Antibodies. <i>Cardiology</i> , 2013, 126, 173-174.	1.4	8
36	<sc>BK</sc> virus nephropathy complicated with meningoencephalitis after kidney transplantation. <i>Pediatric Transplantation</i> , 2014, 18, E48-51.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Predictive Factors of Graft-Censored Failure in Pediatric Kidney Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 1723-1726.	0.6	8
38	Hyperinsulinaemic Hypoglycaemia and Polycystic Kidney Disease – A Rare Case Concerning <i>PMM2</i> Gene Pleiotropy. <i>European Endocrinology</i> , 2020, 16, 66.	1.5	7
39	Haemolytic uraemic syndrome, cardiomyopathy, cutaneous vasculopathy and anti-phospholipid activity. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1891-1892.	0.7	6
40	Apnea/hypopnea index and benzodiazepine use in patients with arterial hypertension and excessive weight. <i>International Journal of Cardiology</i> , 2007, 114, 416-418.	1.7	6
41	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration. , 2015, 6, 17.		6
42	Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 311-317.	0.9	6
43	Non-Hodgkin lymphoma and glomerulonephritis. What kind of relation?. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 854-856.	0.7	5
44	IgA Nephropathy and Antiphospholipid Syndrome. <i>Nephron</i> , 1999, 83, 95-96.	1.8	5
45	Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 630-633.	3.3	5
46	Membranoproliferative Glomerulonephritis and X-Linked Agammaglobulinemia: An Uncommon Association. <i>Case Reports in Pediatrics</i> , 2014, 2014, 1-3.	0.4	5
47	IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 41, 134-135.	1.4	4
48	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. <i>Acta Haematologica</i> , 2008, 120, 11-13.	1.4	4
49	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. <i>Hemodialysis International</i> , 2011, 15, 429-431.	0.9	4
50	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. <i>Renal Failure</i> , 2012, 34, 1355-1358.	2.1	4
51	TLR4 and TLR9 Polymorphisms Effect on Inflammatory Response in End-Stage Renal Disease Patients. <i>European Journal of Inflammation</i> , 2014, 12, 521-529.	0.5	4
52	Acute ischaemic stroke during ambulatory blood pressure monitoring. <i>Lancet, The</i> , 1992, 339, 1113-1114.	18.7	3
53	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. <i>Journal of Vascular Access</i> , 2013, 14, 335-341.	0.9	3
54	Risk factors for mortality in end-stage kidney disease patients under online-hemodiafiltration: three-year follow-up study. <i>Biomarkers</i> , 2016, 21, 544-550.	1.9	3

#	ARTICLE	IF	CITATIONS
55	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. <i>Biomedicines</i> , 2021, 9, 554.	3.2	2
56	Infections Following Kidney Transplant in Children: A Single-Center Study. <i>Open Journal of Nephrology</i> , 2014, 04, 117-124.	0.1	2
57	Hydrocephalus, Hypertension and Renal Failure: Ambulatory Blood Pressure Data. <i>Nephron</i> , 1994, 67, 237-239.	1.8	1
58	Reversible renal failure and SZ alpha1-antitrypsin phenotype. Association with liver disease and ethanol abuse. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 2340-2342.	0.7	1
59	Comparison of Bio-Plex measurements with standard techniques. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 399-402.	2.3	1
60	<b>Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis</b>. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 461-465.	1.4	1
61	Haptoglobin 2â€² phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy. <i>British Journal of Biomedical Science</i> , 2014, 71, 79-81.	1.3	1
62	SP342HEPCIDIN-25 AND TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS ARE INDEPENDENTLY RELATED WITH ERYTHROPOIESIS IN CHRONIC HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i460-i460.	0.7	1
63	Homocysteine levels in pediatric renal transplant recipients. <i>Transplantation Proceedings</i> , 2003, 35, 1093-1095.	0.6	0
64	Tratamento de hiperparatiroidismo secundÃ¡rio grave com paricalcitol em crianÃ§a de 3 anos em diÃ¡lise. <i>Revista Portuguesa De Endocrinologia Diabetes E Metabolismo</i> , 2015, 10, 152-155.	0.1	0
65	Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional Dialysis versus Online-Hemodiafiltration. , 2018, , .		0
66	SP666MACHINE LEARNING IN PREDICTION OF VULNERABLE OR RESILIENT END-STAGE RENAL DISEASE PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
67	SP637INFLAMMATION AND CELL-FREE DNA AS BIOMARKERS FOR THE OUTCOME OF END STAGE RENAL DISEASE PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
68	SP543ASSOCIATION OF PTX3, NT-proBNP AND LEFT VENTRICULAR HYPERTROPHY IN PATIENTS ON DIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
69	FP725PENTRAXIN 3 IN END-STAGE RENAL DISEASE: MULTIPLE RISK BIOMARKER AND PREDICTOR OF ALL-CAUSE MORTALITY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
70	FP730EFFECTS OF STATINS THERAPY ON LDL SUBFRACTIONS AND INFLAMMATION, IN END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
71	MO1023BARDET-BIEDL SYNDROME OR SENIOR-LOKEN SYNDROME? GOING BEYOND THE OBVIOUS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
72	MO1022CENTRAL VENOUS CATHETERS FIRST - THE ACHILLESâ€™ HEEL IN PEDIATRIC HEMODIALYSIS VASCULAR ACCESS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0

#	ARTICLE	IF	CITATIONS
73	Hemodialysis vascular access in children – A retrospective study in a pediatric dialysis unit. Portuguese Journal of Nephrology & Hypertension, 2021, 35, .	0.1	0
74	Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 2009, 71, 233-235.	0.7	0